Thimasarn K, Sirichaisinthop J, Vijaykadga S, Tansophalaks S, Yamokgul P, Laomiphol A, Palananth C, Thamewat U, Tháithong S, Rooney W
Department of Communicable Diseases Control, Ministry of Public Health, Bangkok, Thailand.
Southeast Asian J Trop Med Public Health. 1995 Jun;26(2):204-12.
An in vivo study of the response of P. falciparum to the combination drug, MSP, was conducted among gem miners who contracted malaria from Cambodia in 1991-1992. High level resistance (RII, RIII responses) was observed in 22.5% of the 40 cases attending Mae Sot malaria clinic, west Thailand border, and in 28.1% of the 96 cases attending Bo Rai malaria clinic, east Thailand border. The observations on in vitro studies conducted prior to the MSP treatment and after recrudescence, together with the findings on adequate mefloquine blood levels strongly indicated the serious deterioration of mefloquine efficacy. The first line treatment for the malaria control program needs to be revised and the use of qinghaosu derivatives considered. Intensive measures to combat spreading of the highly resistant strains to other parts of the country should be taken into account.
1991 - 1992年期间,在从柬埔寨感染疟疾的宝石矿工中开展了一项关于恶性疟原虫对联合药物MSP反应的体内研究。在泰国西部边境湄索疟疾诊所就诊的40例病例中,22.5%观察到高水平耐药(RII、RIII反应);在泰国东部边境博赖疟疾诊所就诊的96例病例中,28.1%观察到高水平耐药。在MSP治疗前和复发后进行的体外研究观察结果,以及甲氟喹血药水平充足的研究结果,有力地表明甲氟喹疗效严重恶化。疟疾控制项目的一线治疗需要修订,并考虑使用青蒿素衍生物。应考虑采取强化措施,防止高耐药菌株传播到该国其他地区。